Switzerland· 67244001

Beovu

A brolucizumab product containing brolucizumabum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC S01LA06

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedBeovuATCS01LA06REGISTER NO.67244001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Brolucizumab is registered in 13 of 19 countries.

Countries holding a registration under ATC S01LA06 (brolucizumab), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Brolucizumab · ATC S01LA06

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
brolucizumabum
Manufacturer
—
Country
Switzerland (CH)
ATC code
S01LA06
ATC class
Brolucizumab
Defined daily dose
0.0357 DE, IVT
Swissmedic category
B
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680672440019
    Fertspr 0.165 ml
    CHF 726.5

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Brolucizumab in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All brolucizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Beovu
  • Liechtenstein · Beovu
  • Norway · Beovu

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0afda4e3-710b-4989-a233-723bd1ba9059
GET /v1/drugs/0afda4e3-710b-4989-a233-723bd1ba9059?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "brolucizumabum 120 mg",
  "valid_from": "2024-05-01",
  "limitations": "[{\"description\":\"Für die Behandlung der exsudativen (feuchten) altersbezogenen Makuladegeneration (AMD).<br>\\nBEOVU darf ausschliesslich durch qualifizierte Ophthalmochirurgen der A-, B- und C-Zentren/Kliniken (gemäss der Liste der Weiterbildungszentren der FMH (http://www.siwf-register.ch) zu Lasten der obligatorischen Krankenpflegeversicherung (OKP) angewendet werden.<br>\\nAusnahmeregelung: Die Ausbildungskliniken A, B und C sind berechtigt, mit niedergelassenen Ophthalmochirurgen zu kooperieren, um eine patientennahe Versorgung zu gewährleisten.<br>\\nDie Kooperation geschieht auf einvernehmlicher Basis zwischen beiden Partnern und gemäss folgenden Bedingungen:<br>\\na) Die Ausbildungsklinik führt die Erstuntersuchung oder die Bestätigung der Diagnose durch. Dies muss für die Krankenkassen belegt werden.<br>\\nb) Bei Einigung auf die zugelassene Indikation darf auch der niedergelassene Arzt den Patienten weiterbehandeln.<br>\\nDie gleichzeitige Behandlung beider Augen eines Patienten bedarf der Bewilligung des Krankenversicherers nach vorgängiger Konsultation des Vertrauensarztes.<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2025-12-01\",\"validTo\":\"2027-04-30\"}]",
  "galenic_form": "Inj Lös 6 mg/0.05ml Fertigspr",
  "therapeutic_area": null,
  "sl_inclusion_date": "2020-06-01",
  "self_retention_pct": 10
}

See everything about brolucizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.